Funxion Drug Interactions

Drugs affecting hepatic microsomal enzymes: In vitro drug metabolism showed that pregabalin at concentrations which were, in general, 10-fold greater than observed in Phase 2/3 clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2D6, CYP2E1, and CYP3A4 enzyme systems.
Anticonvulsants: In vitro and in vivo studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drugs interactions. There are no clinically significant pharmacokinetic interactions between pregabalin and the following: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used AEDs.
ACE inhibitors: Potential pharmacologic interaction with ACE inhibitors (e.g., increased risk of developing angioedema).
Tiagabine: In patients with partial seizures, tiagabine had no clinically significant effect on pregabalin clearance.
Gabapentin: Gabapentin pharmacokinetics after single and multiple dose administration were unaltered by pregabalin coadministration. The rate of pregabalin's absorption was reduced by approximately 26% (single dose administration) and 18% (multiple dose administration) based on lower C_max values; however, the extent of pregabalin max absorption was unaffected by gabapentin coadministration.
Oral contraceptives: Concomitant use with pregabalin had no effect on the steady state pharmacokinetics of norethindrone and ethinyl estradiol in healthy subjects.
Lorazepam, oxycodone and alcohol: Multiple dose administration of pregabalin had no effect on the rate and extent of lorazepam, oxycodone, and alcohol. Likewise, single dose administration of lorazepam, oxycodone, and alcohol had no clinically significant effect on the steady state pharmacokinetics of pregabalin.
Multiple oral doses of pregabalin concomitantly used with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. Pregabalin may potentiate the effects of alcohol and lorazepam. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
In postmarketing experience, there are reports of respiratory failure and coma in patients taking pregabalin alone or in combination with other CNS depressants.
Antidiabetic agents: A pharmacokinetic analysis showed no clinically significant effect on pregabalin clearance with the concomitant use of diuretics, oral hypoglycemic (e.g. glyburide, metformin), and insulin. Higher frequencies of weight gain and peripheral edema were reported in patients taking both pregabalin and a thiazolidinedione antidiabetic agent compared to patients taking either drug alone. As the thiazolidinedione class of antidiabetic drugs or pregabalin can cause weight gain and/or fluid retention alone or together, possibly exacerbating or leading to heart failure, caution should be exercised when co-administering pregabalin and these drugs.
Furosemide: Furosemide does not appear to affect the pharmacokinetics of pregabalin.